| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Accounting for Price Endogeneity in Airline Itinerary Choice Models: An Application to Continental U.S. Markets |
0 |
0 |
1 |
46 |
0 |
1 |
3 |
85 |
| Assets with "Warts": How Reliable is the Market for Technology? |
0 |
0 |
0 |
8 |
0 |
0 |
1 |
38 |
| Behind the Scenes: Sources of Complementarity in R&D |
0 |
0 |
0 |
16 |
0 |
0 |
1 |
76 |
| Black Populations and Economic Growth: An Extreme Bounds Analysis of Mississippi County-Level Data |
0 |
0 |
0 |
37 |
0 |
1 |
4 |
258 |
| Blockbusters, Sequels and the Nature of Innovation |
8 |
11 |
11 |
11 |
9 |
14 |
14 |
14 |
| Conveying Quality and Value in Emerging Industries: Star Scientists and the Role of Learning in Biotechnology |
0 |
0 |
0 |
34 |
0 |
0 |
1 |
221 |
| Corporate Venture Capital as a Real Option in the Markets for Technology |
0 |
0 |
0 |
71 |
0 |
0 |
4 |
101 |
| Do Stronger IPR Incentivize Female Participation in Innovation? Evidence from Chinese AI Patents |
1 |
1 |
7 |
13 |
2 |
3 |
19 |
39 |
| Don’t Throw the Baby Out With the Bathwater: Firm Response to Downstream Product Shocks |
0 |
1 |
10 |
18 |
1 |
3 |
17 |
27 |
| Explaining Preferences for Control Rights in Strategic Alliances: A Property Rights and Capabilities Perspective Approach |
0 |
0 |
0 |
29 |
0 |
0 |
2 |
77 |
| Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth |
0 |
0 |
0 |
61 |
1 |
1 |
1 |
424 |
| Federal, State, and Local Governments: Evaluating their Separate Roles in US Growth |
0 |
0 |
0 |
47 |
0 |
2 |
5 |
365 |
| Federal, State, and Local Governments:Evaluating their Separate Roles in US Growth |
0 |
0 |
0 |
12 |
0 |
0 |
0 |
142 |
| Federal, state, and local governments: evaluating their separate roles in US growth |
0 |
0 |
1 |
4 |
0 |
2 |
6 |
37 |
| Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation |
0 |
1 |
1 |
41 |
2 |
9 |
14 |
105 |
| Growth and Convergence across the U.S: Evidence from County-Level Data |
0 |
0 |
1 |
255 |
0 |
0 |
5 |
762 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
0 |
0 |
204 |
0 |
0 |
7 |
621 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
1 |
2 |
15 |
0 |
1 |
4 |
174 |
| Growth and Convergence across the US: Evidence from County-Level Data |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
97 |
| Growth and Convergence across the United States: Evidence from County-Level Data |
0 |
0 |
0 |
2 |
1 |
2 |
7 |
23 |
| Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data |
0 |
0 |
0 |
209 |
0 |
1 |
2 |
1,129 |
| Heterogeneity in Convergence Rates and Income Determination across U.S. States: Evidence from County-Level Data |
0 |
0 |
0 |
2 |
0 |
1 |
4 |
98 |
| Heterogeneous Convergence |
0 |
0 |
1 |
39 |
1 |
1 |
4 |
335 |
| Heterogeneous Convergence |
0 |
0 |
0 |
14 |
0 |
0 |
1 |
93 |
| Heterogeneous Convergence |
0 |
0 |
0 |
15 |
0 |
0 |
0 |
93 |
| Heterogeneous Convergence |
0 |
0 |
0 |
57 |
0 |
0 |
2 |
204 |
| Heterogeneous convergence |
0 |
0 |
0 |
2 |
0 |
0 |
4 |
29 |
| Intra-alliance performance, control rights, and today's split of tomorrow's value |
0 |
0 |
0 |
85 |
0 |
1 |
1 |
226 |
| Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data |
0 |
0 |
2 |
426 |
2 |
8 |
10 |
3,816 |
| Many Types of Human Capital and Many Roles in U.S. Growth: Evidence from County-Level Educational Attainment Data |
0 |
0 |
0 |
11 |
0 |
2 |
7 |
121 |
| Market Size and Research: Evidence from the Pharmaceutical Industry |
0 |
0 |
0 |
17 |
0 |
1 |
1 |
54 |
| Moving Beyond the Valley of Death: Regulation and Venture Capital Investments in Early-Stage Biopharmaceutical Firms |
0 |
0 |
0 |
42 |
0 |
0 |
1 |
61 |
| Pediatric Drug Adherence and Parental Attention: Evidence from Comprehensive Claims Data |
0 |
0 |
0 |
1 |
1 |
1 |
3 |
13 |
| Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry |
0 |
0 |
0 |
57 |
0 |
1 |
2 |
269 |
| Research and Market Structure: Evidence from an Antibiotic-Resistant Pathogenic Outbreak |
0 |
0 |
0 |
2 |
0 |
0 |
2 |
16 |
| Robust Correlates of County-Level Growth in the U.S |
0 |
0 |
0 |
39 |
0 |
0 |
3 |
173 |
| Robust correlates of county-level growth in the United States |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
| Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
30 |
1 |
1 |
3 |
127 |
| Sigma Convergence Versus Beta Convergence: Evidence from U.S. County-Level Data (revised version) |
0 |
0 |
1 |
36 |
0 |
0 |
2 |
127 |
| Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
20 |
| Sigma Convergence versus Beta Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
1 |
151 |
0 |
0 |
5 |
530 |
| Sigma-Convergence Versus Beta-Convergence: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
522 |
0 |
1 |
1 |
1,664 |
| The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
56 |
1 |
1 |
2 |
155 |
| The Direct and Indirect Effects of Small Business Administration Lending on Growth: Evidence from U.S. County-Level Data |
0 |
0 |
0 |
46 |
0 |
0 |
6 |
110 |
| The Effect of Contractual Complexity on Technology Sourcing Agreements |
0 |
0 |
0 |
40 |
0 |
0 |
1 |
260 |
| The Impact of Patenting on New Product Introductions in the Pharmaceutical Industry |
0 |
0 |
0 |
120 |
1 |
1 |
3 |
393 |
| The Role of Assets In Place: Loss of Market Exclusivity and Investment |
0 |
0 |
0 |
11 |
0 |
0 |
1 |
36 |
| Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling |
0 |
0 |
0 |
14 |
1 |
1 |
2 |
50 |
| Total Working Papers |
9 |
15 |
39 |
2,976 |
24 |
61 |
189 |
13,900 |
LogEc is hosted by the
Örebro University School of Business.